Dr. Ce-Fan Zhou is a Professor and Doctoral Supervisor, serving as the Vice Dean of Institute of Biomedical Research, Hubei University of Technology. He earned his bachelor's degree from Nanchang University, followed by his master's and doctoral degrees from Wuhan University. Additionally, he is a visiting scholar at the University of Alberta, Canada. Dr. Zhou’s research focuses on the mechanisms underlying the development of gastrointestinal tumors and targeted therapies, particularly the early evolution of pancreatic ductal adenocarcinoma and liver cancer, tumor drug resistance, and the development of targeted peptide drugs. His work primarily addresses areas such as autophagy (organelle autophagy), signal transduction, and lipid metabolism. His research achievements include elucidating the mechanisms of autophagy initiation and fusion, as well as the crosstalk between autophagy and Wnt/β-catenin signaling, which influence the progression of pancreatic cancer and hepatocellular carcinoma. As the first or corresponding author, he has published over 30 SCI papers in prominent journals such as Cell Death & Differentiation, Signal Transduction and Targeted Therapy, Autophagy (x3), Molecular Cancer, Oncogene, Cell Death & Disease, Biomedicine & Pharmacotherapy, and Advanced Biology. Two of these papers are highly cited, contributing to his H-index of 14 and over 2,000 citations. Dr. Zhou is also a board member of the Hubei Society of Hepatobiliary Diseases and a member of various professional organizations, including the American Association for Cancer Research (AACR), the Chinese Society for Cell Biology (CSCB), the American Association for the Advancement of Science (AAAS), and the Canadian Society for Molecular Biosciences (CSMB). To date, he has served as a reviewer for numerous journals, including BMC Cancer (2023, 2024), Scientific Reports (2024a, 2024b), Functional & Integrative Genomics (2023), Cell Division (2023), Autophagy (2022), Signal Transduction and Targeted Therapy (2023, 2024), and Theranostics (2024).